Sunshine Biopharma, Inc.
SBFM
$1.05
$0.021.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.58M | 9.42M | 9.41M | 8.90M | 9.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.58M | 9.42M | 9.41M | 8.90M | 9.60M |
| Cost of Revenue | 5.55M | 6.34M | 5.99M | 6.17M | 6.50M |
| Gross Profit | 3.03M | 3.07M | 3.42M | 2.73M | 3.09M |
| SG&A Expenses | 4.39M | 3.27M | 4.03M | 3.64M | 4.81M |
| Depreciation & Amortization | 98.90K | 95.80K | 72.50K | 64.80K | 65.40K |
| Other Operating Expenses | 126.50K | 119.90K | 112.70K | 110.20K | 108.80K |
| Total Operating Expenses | 10.24M | 9.95M | 10.40M | 10.20M | 11.63M |
| Operating Income | -1.66M | -532.00K | -992.80K | -1.30M | -2.04M |
| Income Before Tax | -1.73M | -1.02M | -1.98M | -1.22M | -2.29M |
| Income Tax Expenses | 408.40K | -137.40K | -209.20K | -40.20K | -128.70K |
| Earnings from Continuing Operations | -2.14M | -883.80K | -1.77M | -1.18M | -2.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.14M | -883.80K | -1.77M | -1.18M | -2.16M |
| EBIT | -1.66M | -532.00K | -992.80K | -1.30M | -2.04M |
| EBITDA | -1.56M | -435.80K | -920.30K | -1.23M | -1.97M |
| EPS Basic | -0.44 | -0.19 | -0.39 | -0.44 | -1.00 |
| Normalized Basic EPS | -0.21 | -0.06 | -0.13 | -0.28 | -0.66 |
| EPS Diluted | -0.44 | -0.19 | -0.39 | -0.44 | -1.00 |
| Normalized Diluted EPS | -0.21 | -0.06 | -0.13 | -0.28 | -0.66 |
| Average Basic Shares Outstanding | 4.85M | 4.56M | 4.50M | 2.70M | 2.15M |
| Average Diluted Shares Outstanding | 4.85M | 4.56M | 4.50M | 2.70M | 2.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |